BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 18854283)

  • 1. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?
    Janikova A; Bolcak K; Pavlik T; Mayer J; Kral Z
    Clin Lymphoma Myeloma; 2008 Oct; 8(5):287-93. PubMed ID: 18854283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.
    Zinzani PL; Musuraca G; Alinari L; Fanti S; Tani M; Stefoni V; Marchi E; Fina M; Pellegrini C; Castellucci P; Farsad M; Baccarani M
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):291-5. PubMed ID: 17324337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
    Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
    Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients.
    Cervino AR; Pomerri F; Alfieri R; Sileni VC; Castoro C; Galuppo S; Evangelista L
    Nucl Med Commun; 2014 Feb; 35(2):160-8. PubMed ID: 24220054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
    Gallamini A; Rigacci L; Merli F; Nassi L; Bosi A; Capodanno I; Luminari S; Vitolo U; Sancetta R; Iannitto E; Trentin L; Stelitano C; Tavera S; Biggi A; Castagnoli A; Versari A; Gregianin M; Pelosi E; Torchio P; Levis A
    Haematologica; 2006 Apr; 91(4):475-81. PubMed ID: 16585014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential clinical role of fluorodeoxyglucose-positron emission tomography in assessing primary or secondary lymphomas of the parotid gland.
    Basu S; Mahne A; Iruvuri S; Alavi A
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):309-14. PubMed ID: 17324340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.
    Iwamuro M; Okada H; Takata K; Shinagawa K; Fujiki S; Shiode J; Imagawa A; Araki M; Morito T; Nishimura M; Mizuno M; Inaba T; Suzuki S; Kawai Y; Yoshino T; Kawahara Y; Takaki A; Yamamoto K
    World J Gastroenterol; 2012 Nov; 18(44):6427-36; discussion p.6434. PubMed ID: 23197888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma.
    Lu Z; Lin M; Downe P; Chong S; Ling S
    Ann Nucl Med; 2014 Oct; 28(8):805-11. PubMed ID: 25008291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.
    Carrillo-Cruz E; Marín-Oyaga VA; Solé Rodríguez M; Borrego-Dorado I; de la Cruz Vicente F; Quiroga Cantero E; Manzanares Pérez M; Capote FJ; Ramírez Sánchez MJ; Espigado Tocino I; Pérez-Vega H; Vázquez-Albertino R; Pérez-Simón JA
    Eur J Haematol; 2015 Jan; 94(1):23-30. PubMed ID: 24520874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.
    Karam M; Novak L; Cyriac J; Ali A; Nazeer T; Nugent F
    Cancer; 2006 Jul; 107(1):175-83. PubMed ID: 16721817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma.
    Bishu S; Quigley JM; Bishu SR; Olsasky SM; Stem RA; Shostrom VK; Holdeman KP; Paknikar S; Armitage JO; Hankins JH
    Leuk Lymphoma; 2007 Aug; 48(8):1548-55. PubMed ID: 17701586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma.
    Wirth A; Foo M; Seymour JF; Macmanus MP; Hicks RJ
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):213-9. PubMed ID: 18295982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading.
    Wöhrer S; Jaeger U; Kletter K; Becherer A; Hauswirth A; Turetschek K; Raderer M; Hoffmann M
    Ann Oncol; 2006 May; 17(5):780-4. PubMed ID: 16497824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.